



Solving the airway management challenge with simplicity

- Novel
- Patented
- Disruptive

This document contains forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions and current expectations, which could cause the Company's actual results to differ materially from those anticipated in such forward-looking statements. You should not rely on forward-looking statements as guarantees, assurances or predictions of future events. This document is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company



Problem Peri-Operative

Airway management procedures are complex and difficult

40%

Bucking on anesthesia
emergence

>25%

Hemodynamic challenges
and complications

20%

Increase in hospital costs
and **1-day** extra stay

Problem Pre-Hospital

Eroding skills limit intubations and patient outcomes

up to **40%**

Non-perioperative
complication rate

1 in 3

Fail on first
attempt

33%


Decrease in pre-hospital
intubation attempts

Solution


All-in-one transitional
airway management device



- ✓ No Clinical Trials
- ✓ No new Insurance Codes
- ✓ No experience needed



Competition



i-Gel SGA & generic ETT **LMA Fastrach® & ETT** *(sold separately)* **Epic Airway®**

Device offering simplicity & security

×

×

✓

Transition without breathing interruption

×

×

✓

Staged intubation, extubation & less “bucking”

×

✓

✓

Total “transitional procedure” Cost (LM to ETT)

Includes: device, support devices, pharmaceuticals & labor/OR costs

\$2150

\$2000

\$650

Protection

Addressing 20 years of stagnant airway innovation



Design, Method & Utility

- ✔ US – 4 issued; 2 in-process
- ✔ EU – 2 issued; 8 validations



Trademark

- ✔ Registered EPIC Airway®


Freedom To Operate

- ✔ Initial FTO complete
- ✔ Final FTO Q4/2024

Market Size



Go to Market



Commercialization

Regions

Hospital Dense
US States

Segments

Peri-Hospital

Applications

Specialty
Surgeries

Marketing & Sales

YEAR 1

Launch & clinical
“Friends of Epic”

YEAR 2

Scale for broad
national adoption
(B2B)

YEAR 3

GPO & Distributor
Driver

Financials



70x

\$8M

Post Money Valuation

\$550M

5-Year Valuation
Post- Commercialization



Meet our Team

Executive Team



Eric Moses
MD, MBA
CEO, CMO
Co-Founder



Keith McKenna
COO, CFO



Sridhar Musuku
MD
Director of Innovation
Co-Founder



Advisory Team



Andrew Gano
MBA
GM | Advisor
Business Development



Stephen Harper
MD
Clinical Advisor



Mark Deshur
MD, MBA FASA
Clinical Advisor



Strategic Partners

Industry Leaders and Experience



Low-Cost Production

Contract Manufacturer with 20 years AM device history



Delivers FDA 510k

Pre-existing Aptyx relationships and AM device commercialization exp.



Customer Discovery

I-Corp sponsor and mentor support and facilitation




Pre-Clinical Validation

Renowned leader in cadaver studies and research



Timeline




Use of Funds & Ask

Product Commercialization



Use of Funds

- ✓ Clinical Simulation Testing
- ✓ Operations
- ✓ Product Development
- ✓ V&V Testing
- ✓ Design & Tooling
- ✓ Legal and IP



\$830,000

Cumulative Equity Raised
Friends & Family

\$2M




Current Fixed Equity Round

Q4/2024

Closing Round



Creating **innovation** with low-tech airway products

-  Scan QR for a meeting
-  investor@epicairwaysystems.com
-  www.epicairwaysystems.com



DISCLAIMER/CAUTIONARY STATEMENT

The purpose of the information in this presentation ("Presentation") is to describe the material aspects of the current and projected business of Epic Airway Systems, Inc., a Delaware corporation ("Company"). Receipt and acceptance of this Presentation (including viewing this Presentation as part of an oral presentation by the principals or authorized agents of the Company) shall constitute an agreement by you (the "Recipient") that, among other things, this Presentation shall not in any manner whatsoever be copied, reproduced, modified, or distributed to any third party, either in whole or in part, without the prior written consent of the Company. All information contained herein shall be kept confidential by the Recipient, and the Recipient shall not reveal or disclose to any third party without written consent of the Company the information that has been made available to the Recipient.

While the information set forth in the Presentation is deemed by the Company to be accurate, the Company shall not be held liable for the accuracy of, or omissions from, this Presentation and for any other written or oral communication transmitted to the Recipient and any other party in the course of its evaluation of transactions involving the Company. It should be understood that all information provided in this Presentation is provided "AS IS" without warranty of any kind. In particular, the Company may not update this Presentation on a daily or other regular basis. As such, the information and materials contained in this Presentation may be out of date or include omissions or other errors. In addition, the Company may change the information provided in this Presentation at any time without notice and the Company will not be liable in any way for possible consequences of such changes.

This Presentation may contain forward-looking statements, including statements about the Company's beliefs and expectations and/or the Company's products and services. These statements are based on current plans, estimates and projections that are subject to significant economic, business, and other uncertainties beyond the Company's control, and therefore Recipients should not place undue reliance on them and the Company makes no representations as to their attainability.

Nothing in this Presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares of the Company in any jurisdiction.